The HLA typing market is expected to register a CAGR of 5.9% over the forecast period.

  • The growing burden of genetic diseases and the increasing number of organ transplants aid as a major contributor in the market growth. According to a recent study of the National Academy of Science, around 10,044 mutations related to IRD-genes were identified all around the world. It is estimated that around 5.5 million would be affected and approximately 2.7 million are the potential carriers of IRD disease-causing mutation globally. Furthermore, advancements in the products related to HLA typing is also expected to boost the market growth.
  • In 2019, Omixon planned to launch a multiplex HLA typing product line, OmniType. It includes all the reagents and software that helps in analyzing the genomic regions of 11 classical HLA loci. Thus, the rising prevalence of diseases and the developments in HLA typing are expected to drive the market growth.

Key Market Trends

Hospital Segment is Expected to Exhibhit a Significant Market Growth in the HLA Typing Market

Th hospital segment is expected to grow at a significant rate in the HLA typing market, due to the increasing number of organ transplantation and the developing infrastructure of hospitals in terms of advanced devices and equipment. For instance, Cambridge University Hospital provides HLA typing tests for solid organ transplantation, haemotopoietic stem cell transplantation, and also for the diagnosis of various diseases, such as rheumatoid arthritis, narcolepsy, beh?et’s disease, etc.

Furthermore, according to the data of Health Resources and Service Administration, in 2019, kidneys were transplanted the most with an approximate number of 23,401, while livers were transplanted for around 8,896 people. Also, in 2019, the next generation sequencing assays shown a better histocompatibility in the hematopoietic stem cell transplantation. Hence, it is expected to thrive the HLA typing market.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America is expected to be a dominant region in the HLA Typing market, owing to the rising burden of genetic diseases and government initiatives to create awareness among people. According to the World Health Organization, almost 6,000 babies born in the United States are affected by Down Syndrome every year. Furthermore, according to a report published in 2018 by Research America, the overall spending in the United States by the federal agencies for medical and healthcare R&D was accounted for around USD 39.5 billion. Therefore, these factors are expected to fuel the growth of the HLA typing market.

Competitive Landscape

Companies are taking initiatives to grow their presence in the HLA Typing market. For instance, in 2109, CareDX Inc. introduced a new product in the market, AlloSeq Tx 17. It is a HLA NGS (Next Generation Sequencing) based on hybrid capture technology. Key players that are expected to be dominant in the HLA Typing market are Thermofisher Scientific Inc., Qiagen, Illumina Inc., F. HOFFMAN-LA ROCHE LIMITED, Bio-Rad Laboratories Inc., Beckton, Dickinson and Company, TBG Diagnostics Ltd, Takara Bio Inc., GenDX, and Omixon Inc.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support